Document Detail


Management of rosiglitazone-induced edema: two case reports and a review of the literature.
MedLine Citation:
PMID:  12396745     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The thiazolidinediones are an important class of insulin-sensitizing agents used for the treatment of type 2 diabetes. Similar to other antidiabetic agents, use of the thiazolidinediones is limited by adverse drug reactions. Specifically, use of the thiazolidinediones is associated with a triad of fluid retention, edema, and weight gain. In premarketing clinical trials, edema was reported to occur infrequently with minimal severity. However, several published cases from postmarketing data demonstrate that thiazolidinedione-induced fluid retention, exhibited by the initial onset of peripheral edema and weight gain, can progress to a more severe form of pulmonary edema that is refractory to diuretic therapy with resolution of symptoms only through discontinuation of the offending thiazolidinedione. In clinical practice, the occurrence of edema secondary to a thiazolidinedione drug may occur more frequently than reported. Two cases presented in this report illustrate a different outpatient management approach that enables both desired glycemic control and minimal fluid retention while using the thiazolidinediones.
Authors:
Fei Wang; Lauren M Aleksunes; Louise A Reagan; Cunegundo M Vergara
Related Documents :
25032205 - 360° fusion for realignment of high grade cervical kyphosis by one step surgery: case ...
11987745 - G-induced vestibular dysfunction ('the wobblies') among aerobatic pilots: a case report...
2375555 - Labetalol hepatotoxicity.
23864745 - Fatal balamuthia amebic encephalitis in a healthy child: a case report with review of s...
956265 - Ataxia-telangiectasia.
9646315 - Lupus pernio with involvement of nasal cavity and maxillary sinus.
Publication Detail:
Type:  Case Reports; Journal Article; Review    
Journal Detail:
Title:  Diabetes technology & therapeutics     Volume:  4     ISSN:  1520-9156     ISO Abbreviation:  Diabetes Technol. Ther.     Publication Date:  2002  
Date Detail:
Created Date:  2002-10-24     Completed Date:  2003-04-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100889084     Medline TA:  Diabetes Technol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  505-14     Citation Subset:  IM    
Affiliation:
Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, Connecticut 06269-2092, USA. fwang@harthosp.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Body Weight
Clinical Trials as Topic
Diabetes Mellitus / drug therapy*
Diabetes Mellitus, Type 2 / drug therapy*
Diuresis / drug effects*
Edema / chemically induced*,  therapy
Female
Hemoglobin A, Glycosylated / metabolism
Humans
Hypoglycemic Agents / adverse effects*
Middle Aged
Obesity*
Thiazoles / adverse effects*
Thiazolidinediones*
Chemical
Reg. No./Substance:
0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Thiazoles; 0/Thiazolidinediones; 122320-73-4/rosiglitazone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ultrasound-assisted insulin delivery and noninvasive glucose sensing.
Next Document:  From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example.